<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017303</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068674</org_study_id>
    <secondary_id>CYTRAN-IM862-302</secondary_id>
    <secondary_id>FHCRC-5156</secondary_id>
    <nct_id>NCT00017303</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytran</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and&#xD;
      by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and&#xD;
      IM-862 may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and&#xD;
      IM-862 in treating patients who have resected stage III ovarian cancer or primary peritoneal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the complete pathologic response rate at second-look surgery in&#xD;
      patients with optimally resected stage III ovarian epithelial or primary peritoneal cancer&#xD;
      treated with adjuvant paclitaxel, carboplatin, and IM-862. II. Determine the safety profile&#xD;
      of this regimen in this patient population. III. Determine the incidence of infectious and&#xD;
      hematologic complications in patients treated with this regimen. IV. Determine the&#xD;
      progression-free survival of patients with no disease or minimal disease burden after initial&#xD;
      therapy, when treated with IM-862 consolidation therapy. V. Correlate angiogenesis markers&#xD;
      and immunologic parameters with response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified&#xD;
      according to participating center. Patients are randomized to one of three IM-862 doses.&#xD;
      Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.&#xD;
      Treatment repeats every 21 days for 6 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Treatment with IM-862 begins within 10 days of chemotherapy initiation&#xD;
      and continues until clinical evidence of disease progression or until 3 days before&#xD;
      second-look surgery. Arm I: Patients receive a low-dose of IM-862 and 2 placebo doses&#xD;
      intranasally daily. Arm II: Patients receive a medium-dose of IM-862 and 2 placebo doses as&#xD;
      in arm I. Arm III: Patients receive higher-dose IM-862 intranasally three times daily.&#xD;
      Patients undergo second-look surgery within 4-8 weeks after completion of the last course of&#xD;
      chemotherapy. Patients with a complete pathologic response or only microscopically detectable&#xD;
      residual disease receive consolidation therapy with IM-862, according to their original&#xD;
      treatment arm. Consolidation therapy begins within 3-14 days after second-look surgery and&#xD;
      continues for 24 weeks in the absence of disease progression. Patients are followed at 6 and&#xD;
      12 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 180 patients (60 per arm) will be accrued for this study within&#xD;
      1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2001</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oglufanide disodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed stage III ovarian epithelial cancer or&#xD;
        primary peritoneal carcinoma of one of the following cell types: Serous adenocarcinoma&#xD;
        Mucinous adenocarcinoma Clear-cell adenocarcinoma Endometrioid Adenocarcinoma (not&#xD;
        otherwise specified) Undifferentiated carcinoma Transitional cell Malignant Brenner's tumor&#xD;
        Mixed epithelial carcinoma No borderline tumor (tumor of low malignant potential) Underwent&#xD;
        prior standard initial cytoreductive surgery within the past 6 weeks Optimally resected&#xD;
        disease with no residual site of disease more than 1 cm in greatest dimension Removal of&#xD;
        all disease extending beyond the reproductive tract Total hysterectomy and bilateral&#xD;
        salpingo-oopherectomy at cytoreductive surgery or in the past&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: GOG 0-2 Life expectancy: Not&#xD;
        specified Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least&#xD;
        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times&#xD;
        upper limit of normal (ULN) Alkaline phosphatase no greater than 3 times ULN SGOT no&#xD;
        greater than 3 times ULN Renal: Creatinine no greater than 2.0 mg/dL Other: No other&#xD;
        malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of&#xD;
        the cervix or breast No other major systemic medical illness that would preclude survival&#xD;
        No poor general condition or medical, social, or psychosocial factors that would preclude&#xD;
        study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy for current&#xD;
        malignancy At least 5 years since prior gene therapy At least 1 year since prior&#xD;
        interleukin-2 (IL-2) At least 1 year since prior sargramostim (GM-CSF) Concurrent&#xD;
        filgrastim (G-CSF) allowed No concurrent gene therapy No concurrent GM-CSF No concurrent&#xD;
        IL-2 No other concurrent angiogenesis inhibitors (e.g., thalidomide, cyclooxygenase-2&#xD;
        inhibitors (e.g., rofecoxib or celecoxib), interferon products, or angiotensin-converting&#xD;
        enzyme inhibitors) Chemotherapy: At least 5 years since prior anticancer chemotherapy No&#xD;
        prior chemotherapy for current malignancy No other concurrent chemotherapy Endocrine&#xD;
        therapy: No prior endocrine therapy for current malignancy At least 1 year since prior&#xD;
        tamoxifen No concurrent tamoxifen Radiotherapy: No prior radiotherapy for current&#xD;
        malignancy Surgery: See Disease Characteristics Other: At least 1 year since prior&#xD;
        experimental or investigational medications No other concurrent experimental or&#xD;
        investigational medications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Paley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pacific Gynecology Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital of Los Gatos</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas School of Medicine-Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Center - Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital - Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - Medical Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2002</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>February 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2004</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>ovarian undifferentiated adenocarcinoma</keyword>
  <keyword>ovarian mixed epithelial carcinoma</keyword>
  <keyword>ovarian serous cystadenocarcinoma</keyword>
  <keyword>ovarian mucinous cystadenocarcinoma</keyword>
  <keyword>ovarian endometrioid adenocarcinoma</keyword>
  <keyword>ovarian clear cell cystadenocarcinoma</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <keyword>Brenner tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

